CABS Entrepreneurship Club Workshop
“Entrepreneurship and Investment“
Date:December 12, Saturday, 1:00-3:00 PM.
Zoom ID: 996 6292 6044
Huijun Zhou, Ph.D., CABS Enterpreneurship Club Program Chair
Dr. Huijun Zhou is CEO and co-founder of Doctor Chain LTD and iDNA Inc. Dr. Zhou received her Ph.D. in molecular biology and genetics from Cornell University and completed her post-doctoral medical genetics training at the Stanford University School of Medicine. She is a clinical molecular geneticist, board-certified by the American Board of Medical Genetics. She currently serves as the Program Chair of Chinese American BioPharmaceutical Society (CABS) Entrepreneurship Club.
Hong I. Wan, Ph.D. is president, chief executive officer and director of Tallac Therapeutics. Previously as chief scientific officer and a member of the founding management at ALX Oncology, she led the team to advance ALX148, a best-in-class myeloid checkpoint inhibitor, for multiple tumor indications. Prior to ALX Oncology, Dr. Wan held various leadership positions at Pfizer and Wyeth Research, where she was responsible for the early development and translational medicine strategy and execution across various therapeutic areas. Dr. Wan started her career at Renovis where she led discovery programs in neuroinflammation. Dr. Wan received her Ph.D. in molecular and cell biology from University of California, Berkeley and A.B. degree in biochemical sciences from Harvard University.
Keting Chu is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development and venture investment.keting is Executive Chairman of the board at Bluejay Therapeutics currently. Keting was previously a partner and venture Partner of Lyfe Capital that is focused on healthcare VC investments in the US and China. Prior to joining Lyfe Capital, Dr. Chu was venture partner at Apple Tree Partners. Before joining Apple Tree Partners, Keting spent fiveyears as VP, Research TAP at The Leukemia and Lymphoma Society (LLS), and is responsible for venture philanthropy. Prior to LLS, Keting co-founded, as head of RnD or CEO, four biotech companies including Five Prime Therapeutics, Bio3, DigitAB and Mission therapeutics. Before that, Keting was the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation and she was responsible for the R&D pipeline of biologic. Keting received her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF).
Lue Sun is now the Vice President of 3E Bioventures, a venture capital focus on healthcare investment. Prior to 3E, Lue worked at Fusion Fund in Palo Alto and led several investments, including Proscia, Loop Genomics, Quantapore, Huma.ai, and Subtle Medical. He received a Ph.D. in Biology from Tsinghua University before joined Fusion. By focusing on cross-sector innovation, Lue has invested and become the board member of Chigene and Subtle Medical since joining 3E. Meanwhile, he also covers deals in AI applications, Med Tech, Diagnostics, and Liver Diseases.
Please Mark Your Calendar
Annual CABS Entrepreneurship Club Innovation Roadshow | January 13, 2021 | Zoom
CALL FOR PROPOSALS
Zoom registration – $0 (USD) - 1000 left
Please register on Zoom: https://zoom.us/webinar/register/9715971753488/WN_kfkngnAaSDSAjvGIxaYycg. Zoom link will be sent to your registration email upon registration.